Silexion Therapeutics Corp · NASDAQ:SLXN
Silexion Therapeutics — Investor Presentation (August 2026)
27 slides from Silexion Therapeutics's investor presentation, Aug 10, 2026
Slide 1: Silencing Oncogenes at the Level of Gene Expression
Sile ncing Oncogenes at the Level of Gene Expression August 2026 Nasdaq: SLXN
Slide 2: Forward-Looking Statement
Forward - Looking Statement The statements contained in this presentation that are not purely historical are forward - looking statements . Our forward - looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or
Slide 3: Shoot the Messenger, Stop Cancer
Shoot the Messenger Stop Cancer Mutated KRAS Proteins Drive Aggressive Cancers Silexion Develops RNA Silencing Treatments that Abolish KRAS Expression designed to be the most efficacious product for KRAS - driven locally a dvanced Tumors (PDAC, CRC, NSCL ) with meaningful improvement in safety over
Slide 4: KRAS Mutations are Highly Prevalent Drivers Across Major Solid Tumors
4 1. Lee, J.K. et al. NPJ Precis Oncol. 2022;6(1):91.; 2. Hirshberg Foundation for Pancreatic Cancer Research. Pancreatic canc er Facts. https://pancreatic.org/pancreatic - cancer/pancreatic - cancer - facts. Pancreatic Ductal Adenocarcinoma (PDAC) Colorectal Cancer (CRC) Non - squamous Non - Small
Slide 5: SIL204: Leading siRNA Program with Significant Market Opportunity
G12D G12V G12C G12A G12R Multiple Other KRAS SIL204: Leading siRNA Program with Significant Market Opportunity KRAS mutations are present in ~92% pancreatic cancer cases 1 ROW=rest of the world. *Number of KRAS G12D/V mutated LAPC were calculated based on KRAS mutations being present in 92% of pancr
Slide 6: Pancreatic Cancer is Often Systemic Before Visible Metastases Appear
BRPC=borderline resectable pancreatic cancer; LAPC = locally advanced pancreatic cancer. Gemenetzis G, et al. Ann Surg . 2019;270(2):340 - 347; Kleeff J, et al. Nat Rev Dis Primers . 2016;2:16022. Local with Micrometastases Metastatic 15 - 25% Resectable + BRPC ~30% LAPC ~50% Metastatic ~75% liver 6
Slide 7: Pancreatic Cancer Remains a High Medical Need Despite RAS Inhibitors
Pancreatic Cancer Remains a High Medical Need Despite RAS Inhibitors 1. National Cancer Institute. Cancer Stat Facts: Pancreatic Cancer. https://seer.cancer.gov/statfacts/html/pancreas.html. 2 . Cancers 2021, 13(18), 4724; https://doi.org/10.3390/cancers13184724. 3. Gemenetzis G, et al. Ann Surg . 2
Slide 8: Silexion siRNA Silences KRAS at the Source
8 Silexion siRNA Silences KRAS at the Source Lead Product: SIL204 F irst - in - class, isoform selective, stable, pan KRAS RNA silencer with delivery system targeting high LDL receptor expressing tumors and micrometastases Targets both active and inactive forms of KRAS Treating closer to the mechani
Slide 9: SIL204 Targets Both Primary Tumor and Metastases
SIL204 Targets Both Primary Tumor and Metastases Combined intratumoral and systemic (subcutaneous) dosing controls primary tumor and metastatic spread Primary pancreatic tumor targeted by Intra - tumoral SIL204 Micrometastatic invasions into liver, lung targeted by S yste mic SIL204 Pancreatic cance
Slide 10: SIL204 Combines KRAS Silencing with Dual Delivery
Potentially the most advanced gene silencing oncology product in clinical development • Potential efficacy advantage from silencing KRAS upstream of inhibitors • Protential safety advantage with KRAS - specific targeting and absent RAS off - target binding • Targets both primary tumor and metastatic
Slide 11: SIL204 Silences KRAS RNA with Corresponding Reduced KRAS Protein
11 0 0.2 0.4 0.6 0.8 1 control 5 nM 50 nM Normalized fold (2 - ∆∆Ct) mRNA **** **** 0 0.2 0.4 0.6 0.8 1 control 5nM 50nM KRAS/ GAPDH Normalized fold KRAS Protein SIL204 Silences KRAS RNA with Corresponding Reduced KRAS Protein Transfection with lipofectamine PK59 human tumor line G12D mutation Analy
Slide 12: SIL204 Broad Inhibition Across Human KRAS Mutations
SIL204 Highly Effective with Broad Inhibition Across Human KRAS Mutations at Sub - nanomolar Concentrations SIL 204 maintains and expands the silencing activity of first generation siG 12 DLoder 12 Model is a co - transfection setup where human KRAS is transfected in mouse Hepa1 - 6 cells with Dual
Slide 13: SIL204 Inhibits Growth of Multiple Mutant KRAS+ Human Tumor Cell Lines
SIL204 Inhibits Growth of Multiple Mutant KRAS+ Human Tumor Cell Lines SIL204 inhibits proliferation across four human cancer cell lines ( CTG assay) 13 Broad antitumor activity at clinically achievable concentrations CTG= CellTiter - Glo IC 90 (ng/mL) IC 90 ( nM ) IC 50 (ng/mL) Cell line KRAS mutat
Slide 14: In Silico Analysis Supports SIL204 Specificity for KRAS
In Silico Analysis Supports SIL204 Specificity for KRAS Predicted binding to KRAS G12V with low predicted off - target activity against HRAS/NRAS • SIL204 binding to KRAS G12V strong ( - 31.8 kcal/mole) • No Off - Target Active Anti - sense Binding indicating l ow risk for side effects. • No effect
Slide 15: Intratumor SIL204 Inhibited Human Pancreatic Cancer Xenograft Growth in Mice
Intratumor Administered SIL 204 Inhibited Human Pancreatic Cancer Xenograft Growth in Mice 15 SIL204 significantly reduced tumor volume and growth while increasing tumor necrosis (cell death) *p<0.05 ; ***p<0.0005 s.c. . = subcutaneous. Day 1: Capan - 1 (KRAS G12V) luciferase cells were xenografted
Slide 16: SIL204 Enhancements Result in Improved Stability
SIL204 Enhancements Result in Improved Stability 16 SIL 204 maintains therapeutic levels in target tissues for > 28 days PK profiles of SIL204 after a single s.c. administration were determined in Sprague Dawley rats using a LC - MS/MS analytical method, in the plasma and after collection f rom kidn
Slide 17: Systemic Administration of siRNA Strongly Supported by Preclinical Data
Systemic Administration of siRNA Strongly Supported by Preclinical Data 17 Subcutaneous SIL204 proved effective in mouse metastatic pancreatic orthotopic models Human tumor cell line Panc - 1 harboring KRAS G 12 D mutation Animal model represents human equivalent dose (HED) of SIL - 204 SC SIL204 ab
Slide 18: SIL204's Anti-Tumor Activity Synergistic with Pancreatic Cancer Chemotherapy
SIL204’s Anti - Tumor Activity Synergistic with Pancreatic Cancer Chemotherapy * p<0.05, ***p<0.0005 Human pancreatic cell line Panc - 1 (G12D) 18 15 25 35 45 Untreated FOLFIRI 50µM FOLFIRI 50µM+SIL-204 Cell Confluence Panc 1 cell confluence after 67 hrs *
Slide 19: Toxicology
Toxicology • Extended single - dose GLP toxicity studies completed in 2 relevant species, aligned with ICH S9 guidance for oncology and confirmed by regulatory agency for initiation of Phase 2/3 clinical trial • Established safety margins of up to 11 - fold over the clinical starting dose. • SIL204
Slide 20: SIL204 Phase 2/3 Clinical Trial Initiated July 2026
SIL 204 Phase 2 / 3 Clinical Trial Initiated July 2026 Dose escalation in LAPC subjects treated with SIL 204 - IR at 3 dose levels + SoC chemotherapy ( n ≈ 15 – 18 ) Primary Objective: Identify Phase 2 expansion doses Randomized, 3 arm study comparing SIL 204 - IR at 2 dose levels + SoC chemo vs SoC
Slide 21: Strategic Collaboration for SIL204 GMP Clinical Supply with European Manufacturers
Strategic Collaboration for SIL 204 GMP Clinical Supply with Leading European Manufacturers Collaboration to leverage Catalent and Axolabs ’ experience in formulation development and manufacturing biologicals to further enhance SIL 204 's therapeutic potential through improved stability, bioavailabi
Slide 22: Silexion Advancing SIL204 Phase 2/3 Development Plan
Silexion advancing SIL 204 Phase 2 / 3 Development Plan GMP clinical supply for Ph 2 / 3 safety run - in manufactured Toxicology complete for Ph 2 / 3 safety run - in Positive scientific advice from the EMA received I nitiation of Ph 2 / 3 approved by Israel ’ s MoH and Germany ’ s BfArM Initiated P
Slide 23: SIL204: First in Class siRNA Targeting KRAS-Driven Cancers
SIL 204 First in class siRNA targeting KRAS - driven cancers • SIL 204 Phase 2 / 3 in locally advanced pancreatic cancer received regulatory approval in Israel and Germany, initiated clinical trial July 2026 ; pre - IND meeting with FDA expected early 2027 • Isoform - selective, pan KRAS silencer, s
Slide 24: Thank You
Thank You Nasdaq: SLXN Ilan Hadar Chairman & Chief Executive Officer email: i hadar@silexion.com Dr. Mitchell Shirvan Chief Scientific and Development Officer email: m shirvan@silexion.com Mirit Horenshtein Hadar, CPA Chief Financial Officer email: mirit@silexion.com
Slide 25: Intellectual Property Protection
Intellectual Property Protection Exclusivity can be extended under country - specific regulatory - based extension rules. Term Submissions Expected protection until 2043 plus estimated extension to 2048 Entered national Phase world wide, SIL - 204 as a composition and for use in treatment of pancrea
Slide 26: World-Renowned Expert Scientific Advisory Board
World - Renowned Expert Scientific Advisory Board Eileen M. O'Reilly, MD Memorial Sloan Kettering, NY, NY Winthrop Rockefeller Endowed Chair of Medical Oncology; Co - Director, Medical Initiatives, David M. Rubenstein Center for Pancreatic Cancer Research; Section Head, Hepatopancreatobi Hana Algul
Slide 27: Highly Experienced Leadership Team
Highly Experienced Leadership Team Ilan Hadar , MBA Chairman and Chief Executive Officer Over 25 years of multinational executive managerial and corporate experience with pharmaceutical and high - tech companies . CEO Pain R eform ( “ PRFX ” ), CFO Foamix Pharmaceuticals Inc . (Currently “ VYNE ” )
Silexion Therapeutics — Investor Presentation (August 2026) on 6ix